Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Akebia TherapeuticsSTU:AX9 +1.87%51 Cyclically Adjusted PB Ratio is 0.75 as of Jul. 15, 2026, which is 50% above its 10-year median of 0.50. GuruFocus rates STU:AX9 with a GF Score™ of 51/100 and a GF Value™ of €1.12 (Fairly Valued). The stock has 5 warning signs investors should review. Among 759 Drug Manufacturers companies, Akebia Therapeutics ranks better than 80.5% on this metric.
The historical rank and industry rank for Akebia Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:
STU:AX9'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.08 Med: 0.5 Max: 1.7
Current: 0.73
During the past years, Akebia Therapeutics's highest Cyclically Adjusted PB Ratio was 1.70. The lowest was 0.08. And the median was 0.50.
STU:AX9's Cyclically Adjusted PB Ratio is ranked better than 80.5% of 759
companies
in the Drug Manufacturers industry
Industry Median: 1.82
vs STU:AX9: 0.73
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Akebia Therapeutics's adjusted book value per share data for the three months ended in Mar. 2026 was €0.088. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €1.63 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Akebia Therapeutics (STU:AX9) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Akebia Therapeutics Cyclically Adjusted PB Ratio Related Terms
Akebia Therapeutics Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Akebia Therapeutics's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akebia Therapeutics Cyclically Adjusted PB Ratio Chart
STU:AX9 vs TKNO, ORGO, SIGA: Cyclically Adjusted PB Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akebia Therapeutics Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Akebia Therapeutics's Cyclically Adjusted PB Ratio falls into.
Akebia Therapeutics Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Akebia Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 0.75 mean?
Akebia Therapeutics (STU:AX9) has a Cyclically Adjusted PB Ratio of 0.75 as of Jul. 15, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Akebia Therapeutics and its competitors. This is 50% above median its historical median of 0.50. Over the past decade, Akebia Therapeutics' Cyclically Adjusted PB Ratio has ranged from 0.08 to 1.70. According to the industry distribution chart, Akebia Therapeutics ranks #148 out of 759 companies in the Drug Manufacturers industry, placing it in the top 19.5%.
Is Akebia Therapeutics' Cyclically Adjusted PB Ratio too high?
Akebia Therapeutics' current Cyclically Adjusted PB Ratio of 0.75 is 50% above median its 10-year median of 0.50. Over the past 10 years, this metric has ranged from a low of 0.08 to a high of 1.70. The Drug Manufacturers industry median Cyclically Adjusted PB Ratio is 1.82. Akebia Therapeutics' value of 0.75 is 58.8% below this industry median. Based on the distribution chart, Akebia Therapeutics ranks #148 out of 759 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Akebia Therapeutics has a GF Score™ of 51/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' Cyclically Adjusted PB Ratio compare to TKNO and ORGO?
According to the Drug Manufacturers industry distribution chart, Akebia Therapeutics ranks #148 out of 759 companies for Cyclically Adjusted PB Ratio. This places Akebia Therapeutics in the top 20% of its industry — outperforming the majority of peers. The industry median Cyclically Adjusted PB Ratio is 1.82. Akebia Therapeutics' value of 0.75 is 58.8% below this benchmark. Historically, Akebia Therapeutics' own Cyclically Adjusted PB Ratio has ranged from 0.08 to 1.70 over the past decade. While the company's 10-year median is 0.50 vs. the industry median of 1.82, Akebia Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Drug Manufacturers company?
The median Cyclically Adjusted PB Ratio among Drug Manufacturers companies is 1.82, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Akebia Therapeutics's current Cyclically Adjusted PB Ratio of 0.75 is 58.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Akebia Therapeutics and its competitors. For the Drug Manufacturers industry, the median Cyclically Adjusted PB Ratio is 1.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akebia Therapeutics's current Cyclically Adjusted PB Ratio is 0.75, which is 50% above median its own 10-year median of 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (STU:AX9) is currently considered Fairly Valued. The stock's GF Value™ is €1.12, compared to a current price of €1.22 — trading 9.2% above its estimated fair value. The current Cyclically Adjusted PB Ratio is 0.75, which is 50% above median its 10-year median of 0.50 and 58.8% below the Drug Manufacturers industry median of 1.82. Akebia Therapeutics' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Akebia Therapeutics (STU:AX9), the current Cyclically Adjusted PB Ratio is 0.75 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Akebia Therapeutics (STU:AX9) Overvalued in 2026?
Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be overvalued.
The current stock price of €1.22 is trading 9.2% above its estimated GF Value™ of €1.12.
GuruFocus considers Akebia Therapeutics to be Fairly Valued.
Key valuation signals for STU:AX9:
Cyclically Adjusted PB Ratio: 0.75 (50% above median its 10-year median of 0.50)
GF Value™: €1.12 vs. price of €1.22 (9.2% above fair value)
Industry Position: 58.8% below the Drug Manufacturers median (#148 of 759)
No single metric tells the full story. See the STU:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
51GF Score
Get the complete analysis for STU:AX9
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AX9 has been successfully added to your 
